Qu – which, according to Parsa, is the fruit of a collaboration between a global team of experienced AI scientists, ...

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after ...

How will AI continue to transform drug development? What’s next for cell and gene therapy? Who will take the crown in the ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

This 18th-20th February, 2025, London will host the premier HR event for European Life Sciences. Join CHROs, CPOs, and HR ...